Market Overview

Morgan Stanley Feels More Positive On Santander Consumer Following Investor Day


In a report published Thursday, Morgan Stanley analyst Cheryl M. Pate reiterated an Overweight rating and $28.00 price target on Santander Consumer USA Holdings Inc (NYSE: SC).

In the report, Morgan Stanley noted, “We come away from SC's investor day more positive on 1) risk-adjusted margins in 2014 vintage/ new business, 2) profitability of the unsecured consumer business, 3) scale in servicing business. Additionally, we believe provisioning should normalize down closer to charge-off levels on average on an annual basis as the reserve additions for 2013 vintage seasoning are likely done. We do expect continued reserve build on new originations. Finally, we expect asset sales / servicing portfolio to ramp in the super-prime to near-prime space, driving stability and higher fee income. SC remains our top pick and weview thecurrent stock level as an attractive entry point.”

Santander Consumer closed on Wednesday at $18.63.

Latest Ratings for SC

Nov 2019MaintainsEqual-Weight
Nov 2019DowngradesBuyNeutral
Sep 2019DowngradesEqual-WeightUnderweight

View More Analyst Ratings for SC
View the Latest Analyst Ratings

Posted-In: Cheryl M. Pate Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (SC)

View Comments and Join the Discussion!

Latest Ratings

VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

Cato Beats Q3 Net Views, Misses Sales Expectations